Pierre Fabre Laboratories sells its immuno-oncology research site located in Saint-Julien-en-Genevois (Haute-Savoie) to Jubilant Biosys Limited

Castres, January 29, 2025 – Pierre Fabre Laboratories and Jubilant Biosys Limited have signed an agreement regarding the sale of the Pierre Fabre research and development site specialized in immuno-oncology located in Saint-Julien-en-Genevois, following the announcement of entering into exclusive negotiations made last August 19.

Jubilant Biosys is a global player in pharmaceutical outsourcing, employing 2,300 people and offering an integrated range from the development of new molecules to the production of biopharmaceuticals. Jubilant Biosys now aims to establish itself in Europe and expand in the fields of biological drugs and conjugated antibodies, which the Saint-Julien-en-Genevois research & development site will enable.  

The sale involves the transfer of the site, its 35 employees, buildings and equipment, and ongoing research projects to Jasmin SAS, a new company incorporated by Pierre Fabre Laboratories, in which Jubilant will acquire 80% equity and Pierre Fabre Laboratories will retain balance 20% equity pursuant to a shareholders’ agreement. 

This sale project follows the repositioning of Pierre Fabre Laboratories' research and development strategy announced in 2023. This new strategy aims to focus innovation activities in oncology on targeted therapies and to consolidate all R&D teams at the Oncopole campus in Toulouse, at the Pierre Fabre Innovation Center.